Literature DB >> 33707224

Bronchiolitis and SARS-CoV-2.

Gregorio Paolo Milani1,2, Valentina Bollati2, Luca Ruggiero3, Samantha Bosis3, Raffaella Maria Pinzani3, Giovanna Lunghi4, Federica Rota2, Laura Dioni2, Anna Luganini5, Carlo Agostoni6,2, Paola Marchisio3,7.   

Abstract

BACKGROUND: It has been speculated that the SARS-CoV-2 was already widespread in western countries before February 2020.
METHODS: We gauged this hypothesis by analysing the nasal swab of infants with either bronchiolitis or a non-infectious disease admitted to the Ospedale Maggiore, Milan (one of the first epicentres of SARS-CoV-2 outbreak in Europe) from November 2019.
RESULTS: The SARS-CoV-2 RNA was never detected in 218 infants with bronchiolitis (95 females, median age 4.9 months) and 49 infants (22 females, median age 5.6 months) with a non-infectious disease between November 2019 and February 2020. On the contrary, two infants hospitalised for bronchiolitis between March and April 2020 tested positive for SARS-CoV-2.
CONCLUSIONS: This study does not support the hypothesis that SARS-CoV-2 was already circulating among infants before the official outbreak of SARS-CoV-2 infection. However, it shows for the first time that SARS-CoV-2 might cause bronchiolitis requiring hospitalisation. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  COVID-19; epidemiology; virology

Year:  2021        PMID: 33707224     DOI: 10.1136/archdischild-2020-321108

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  6 in total

1.  Bronchiolitis epidemics in France during the SARS-CoV-2 pandemic: The 2020-2021 and 2021-2022 seasons.

Authors:  Sophie Vaux; Delphine Viriot; Cécile Forgeot; Isabelle Pontais; Yann Savitch; Agnès Barondeau-Leuret; Serge Smadja; Martine Valette; Vincent Enouf; Isabelle Parent du Chatelet
Journal:  Infect Dis Now       Date:  2022-06-23

2.  Clinical Characteristics of Omicron (B.1.1.529) Variant in Children: A Multicenter Study in Spain.

Authors:  Miguel Ángel Molina Gutiérrez; Lara Sánchez Trujillo; José Antonio Ruiz Domínguez; Ignacio Callejas Caballero; Beatríz García Cuartero; María Ángeles García-Herrero; María Jesús Pascual Marcos; José Tomás Ramos Amador; Carmen Martínez Del Río; María de Ceano-Vivas La Calle
Journal:  Arch Bronconeumol       Date:  2022-06-10       Impact factor: 6.333

3.  Caregivers' Intention to Vaccinate Their Children Under 12 Years of Age Against COVID-19: A Cross-Sectional Multi-Center Study in Milan, Italy.

Authors:  Maurizio Lecce; Gregorio Paolo Milani; Carlo Agostoni; Enza D'Auria; Giuseppe Banderali; Giacomo Biganzoli; Luca Castellazzi; Costanza Paramithiotti; Elisabetta Salvatici; Paola Tommasi; Gian Vincenzo Zuccotti; Paola Marchisio; Silvana Castaldi
Journal:  Front Pediatr       Date:  2022-05-30       Impact factor: 3.569

4.  Bronchiolitis, epidemiological changes during the SARS-CoV-2 pandemic.

Authors:  Monica Balaguer; Iolanda Jordan; Carmina Guitart; Sara Bobillo-Perez; Carme Alejandre; Georgina Armero; Cristian Launes; Francisco Jose Cambra
Journal:  BMC Infect Dis       Date:  2022-01-24       Impact factor: 3.090

5.  Evaluation of reported medical services provided to pediatric viral bronchiolitis diagnoses during the COVID-19 pandemic.

Authors:  Conrad Krawiec; Duane Williams; Vonn Walter; Neal J Thomas
Journal:  Respir Med Res       Date:  2022-04-09

6.  Prevalence of SARS-CoV-2 positivity in infants with bronchiolitis: a multicentre international study.

Authors:  Giorgio Cozzi; Luisa Cortellazzo Wiel; Alessandro Amaddeo; Antonio Gatto; Manuela Giangreco; Adi Klein-Kremer; Samantha Bosis; Davide Silvagni; Carla Debbia; Laura Nanni; Sara Chiappa; Marta Minute; Ilaria Corsini; Giuliana Morabito; Anna Jolanda Gortan; Marco Colombo; Federico Marchetti; Davide Garelli; Arianna Piffer; Fabio Cardinale; Nitai Levy; Antonietta Curatola; Bojana Gojsina; Suvradeep Basu; Egidio Barbi; Aleksandar Sovtic
Journal:  Arch Dis Child       Date:  2022-06-15       Impact factor: 4.920

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.